Roche readies cancer data for ASCO

Fresh on the heels of its takeover of Genentech, Roche is preparing to take the stage at ASCO later this month to tout its continuing success in developing targeted cancer therapies. New mid- and late-stage data on Herceptin will be released along with new insights on Avastin and Tarceva in lung cancer. And Roche says it has positive early data on its BRAF inhibitor in malignant melanoma. Combining Roche and Genentech's work created an oncology program with 27 therapeutics in the clinic. Report